Literature DB >> 12612307

Relationship of anti-GM-CSF antibody concentration, surfactant protein A and B levels, and serum LDH to pulmonary parameters and response to GM-CSF therapy in patients with idiopathic alveolar proteinosis.

J F Seymour1, I R Doyle, K Nakata, J J Presneill, O D Schoch, E Hamano, K Uchida, R Fisher, A R Dunn.   

Abstract

BACKGROUND: Conventional measures of the severity of alveolar proteinosis (AP) include alveolar-arterial oxygen gradient ([A - a]DO(2)), vital capacity (VC), and carbon monoxide transfer factor (TLCO), but alternative serological measures have been sought. Granulocyte-macrophage colony stimulating factor (GM-CSF) neutralising autoantibody is found in patients with idiopathic acquired AP. We have investigated the interrelationships between the levels of this antibody and those of surfactant protein (SP)-A and -B, lactate dehydrogenase (LDH), and conventional measures of disease severity, and the capacity of these parameters to predict the response to rhGM-CSF treatment.
METHODS: Blood levels of anti-GM-CSF antibodies, SP-A, SP-B, LDH, and [A - a]DO(2), VC, and TLCO were measured before rhGM-CSF treatment and every 2 weeks thereafter in 14 patients with AP.
RESULTS: At baseline, high levels of anti-GM-CSF antibodies and increased SP-A and SP-B levels were seen in all patients, and LDH was raised in 83%. SP-A was highly correlated with [A - a]DO(2), VC, and TLCO (p</=0.02), but other markers were not. Only a normal LDH level was predictive of a response to rhGM-CSF treatment (p=0.03). During treatment a correlation between conventional and serological variables within patients was seen only between SP-A and [A - a]DO(2) (p=0.054), LDH levels and [A - a]DO(2) (p=0.010), and LDH levels and VC (p=0.019).
CONCLUSIONS: Of the serological parameters studied, only SP-A and LDH levels were correlated with conventional measures of disease severity, with LDH most accurately reflecting [A - a]DO(2) and vital capacity. Only a normal LDH level predicted a higher likelihood of response to treatment with GM-CSF.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12612307      PMCID: PMC1746613          DOI: 10.1136/thorax.58.3.252

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  24 in total

1.  Anti-GM-CSF antibodies in paediatric pulmonary alveolar proteinosis.

Authors:  P Latzin; M Tredano; Y Wüst; J de Blic; T Nicolai; B Bewig; F Stanzel; D Köhler; M Bahuau; M Griese
Journal:  Thorax       Date:  2005-01       Impact factor: 9.139

2.  Autoantibody-Mediated Pulmonary Alveolar Proteinosis in Rasgrp1-Deficient Mice.

Authors:  Andrew Ferretti; Jarrod R Fortwendel; Sarah A Gebb; Robert A Barrington
Journal:  J Immunol       Date:  2016-06-08       Impact factor: 5.422

3.  Atypical pulmonary alveolar proteinosis presenting as a mixed nodular ground-glass opacity with focal mucinosis mimicking lung cancer.

Authors:  Tsutomu Shinohara; Hiroyuki Hino; Shino Imanishi; Keishi Naruse; Yuji Ohtsuki; Fumitaka Ogushi
Journal:  J Thorac Dis       Date:  2018-09       Impact factor: 2.895

4.  A standardized blood test for the routine clinical diagnosis of impaired GM-CSF signaling using flow cytometry.

Authors:  Yoshiomi Kusakabe; Kanji Uchida; Takahiro Hiruma; Yoko Suzuki; Tokie Totsu; Takuji Suzuki; Brenna C Carey; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  J Immunol Methods       Date:  2014-07-26       Impact factor: 2.303

5.  Patient-derived granulocyte/macrophage colony-stimulating factor autoantibodies reproduce pulmonary alveolar proteinosis in nonhuman primates.

Authors:  Takuro Sakagami; David Beck; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Koh Nakata; Gary Keller; Robert E Wood; Susan E Wert; Machiko Ikegami; Jeffrey A Whitsett; Maurizio Luisetti; Stella Davies; Jeffrey P Krischer; Alan Brody; Fred Ryckman; Bruce C Trapnell
Journal:  Am J Respir Crit Care Med       Date:  2010-03-11       Impact factor: 21.405

6.  An open-label trial of rituximab therapy in pulmonary alveolar proteinosis.

Authors:  M S Kavuru; A Malur; I Marshall; B P Barna; M Meziane; I Huizar; H Dalrymple; R Karnekar; M J Thomassen
Journal:  Eur Respir J       Date:  2011-04-08       Impact factor: 16.671

7.  Characteristics of a large cohort of patients with autoimmune pulmonary alveolar proteinosis in Japan.

Authors:  Yoshikazu Inoue; Bruce C Trapnell; Ryushi Tazawa; Toru Arai; Toshinori Takada; Nobuyuki Hizawa; Yasunori Kasahara; Koichiro Tatsumi; Masaaki Hojo; Toshio Ichiwata; Naohiko Tanaka; Etsuro Yamaguchi; Ryosuke Eda; Kazunori Oishi; Yoshiko Tsuchihashi; Chinatsu Kaneko; Toshihiro Nukiwa; Mitsunori Sakatani; Jeffrey P Krischer; Koh Nakata
Journal:  Am J Respir Crit Care Med       Date:  2008-01-17       Impact factor: 21.405

8.  Granulocyte/macrophage-colony-stimulating factor autoantibodies and myeloid cell immune functions in healthy subjects.

Authors:  Kanji Uchida; Koh Nakata; Takuji Suzuki; Maurizio Luisetti; Masato Watanabe; Diana E Koch; Carrie A Stevens; David C Beck; Lee A Denson; Brenna C Carey; Naoto Keicho; Jeffrey P Krischer; Yoshitsugu Yamada; Bruce C Trapnell
Journal:  Blood       Date:  2009-03-12       Impact factor: 22.113

9.  Clinical significance of anti-GM-CSF antibodies in idiopathic pulmonary alveolar proteinosis.

Authors:  F-C Lin; G-D Chang; M-S Chern; Y-C Chen; S-C Chang
Journal:  Thorax       Date:  2006-03-03       Impact factor: 9.139

Review 10.  Rare lung disease II: pulmonary alveolar proteinosis.

Authors:  Stephen C Juvet; David Hwang; Thomas K Waddell; Gregory P Downey
Journal:  Can Respir J       Date:  2008 May-Jun       Impact factor: 2.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.